Amgen reported that its weight loss drug MariTide helped obese patients lose up to 20% of their body weight over one year in a phase 2 study.[1] The study included 465 obese or overweight people who were randomly assigned to placebo or various doses of MariTide given monthly, including fixed doses and gradual increases.[1] Another 127 obese or overweight patients with type 2 diabetes were assigned to placebo or monthly fixed doses.[1] Weight loss results are in line with Zepbound and Wegovy, according to analysts, but MariTide's discontinuation rate was higher.[1] Amgen did not provide full details of the study, which it plans to disclose at future medical meetings and in peer-reviewed journals.[1] The company will launch a Phase 3 clinical trial program for MariTide in patients with obesity and heart disease, sleep apnea, kidney disease and other obesity-related conditions.[1] MariTide is a bispecific GLP-1 receptor agonist and GIP receptor antagonist administered subcutaneously monthly or less frequently.[4]